-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Megan McHugh, PhD

Articles by Megan McHugh, PhD

The Longitudinal Impact of Aligning Forces for Quality on Measures of Population Health, Quality and Experience of Care, and Cost of Care

ByYunfeng Shi, PhD,Dennis P. Scanlon, PhD,Raymond Kang, MA,Megan McHugh, PhD,Jessica Greene, PhD,Jon B. Christianson, PhD,Muriel Jean-Jacques, MD, MAPP,Yasmin Mahmud, MPH,Jeffrey A. Alexande

August 23rd 2016

Evaluating a Complex, Multi-Site, Community-Based Program to Improve Healthcare Quality: The Summative Research Design for the Aligning Forces for Quality Initiative

ByDennis P. Scanlon, PhD,Laura J. Wolf, MSW,Jeffrey A. Alexander, PhD,Jon B. Christianson, PhD,Jessica Greene, PhD,Muriel Jean-Jacques, MD, MAPP,Megan McHugh, PhD,Yunfeng Shi, PhD,Brigitt Leitze

August 23rd 2016

Summative Evaluation Results and Lessons Learned From the Aligning Forces for Quality Program

ByDennis P. Scanlon, PhD,Jeffrey A. Alexander, PhD,Megan McHugh, PhD,Jeff Beich, PhD,Jon B. Christianson, PhD,Jessica Greene, PhD,Muriel Jean-Jacques, MD, MAPP,Brigitt Leitzell, MS,Yunfeng Shi,

August 23rd 2016

Improving Care Delivery at the Community Level: An Examination of the AF4Q Legacy

ByMegan McHugh, PhD,Jillian B. Harvey, MPH, PhD,Jaime Hamil, MPH,Dennis P. Scanlon, PhD

August 23rd 2016

Employer-Led Efforts to Improve the Value of Health Spending

ByMegan McHugh, PhD,Claude R. Maechling, PhD,Dorothy D. Dunlop, PhD,Linda Oâ€™Dwyer, MSLIS, MA,Dustin D. French, PhD,Rahul K. Khare, MD, MS,Anna P. Nannicelli, MPH, MSW,Alexandra R. Brown, BA,a

March 14th 2016

Findings from a systematic review show that employer-led efforts to date have produced few promising strategies for improving the value of health spending.

Latest Updated Articles

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS